# Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors

> **NCT00165230** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 32 (—)

## Conditions studied

- Neuroendocrine Tumor

## Interventions

- **DRUG:** Thalidomide
- **DRUG:** Temodar

## Key facts

- **NCT ID:** NCT00165230
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2006-07
- **Final completion:** 2006-07
- **Target enrollment:** 32 (—)
- **Last updated:** 2009-04-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00165230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00165230, "Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00165230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*